BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15843468)

  • 1. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
    Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
    J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
    Quarles LD
    Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
    Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
    J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
    Argiro L; Desbarats M; Glorieux FH; Ecarot B
    Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The wrickkened pathways of FGF23, MEPE and PHEX.
    Rowe PS
    Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
    Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
    J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenic role of Fgf23 in Hyp mice.
    Liu S; Zhou J; Tang W; Jiang X; Rowe DW; Quarles LD
    Am J Physiol Endocrinol Metab; 2006 Jul; 291(1):E38-49. PubMed ID: 16449303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
    Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
    Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
    Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
    Rowe PS
    Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MEPE cleavage by Phex.
    Guo R; Rowe PS; Liu S; Simpson LG; Xiao ZS; Quarles LD
    Biochem Biophys Res Commun; 2002 Sep; 297(1):38-45. PubMed ID: 12220505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
    Zelenchuk LV; Hedge AM; Rowe PS
    Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
    Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
    PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.
    Mohamed FF; Hoac B; Phanrungsuwan A; Tan MH; Giovani PA; Ghiba S; Murshed M; Foster BL; McKee MD
    Bone; 2023 Nov; 176():116886. PubMed ID: 37634682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
    David V; Martin A; Hedge AM; Drezner MK; Rowe PS
    Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.
    Coyac BR; Hoac B; Chafey P; Falgayrac G; Slimani L; Rowe PS; Penel G; Linglart A; McKee MD; Chaussain C; Bardet C
    J Dent Res; 2018 Feb; 97(2):184-191. PubMed ID: 28880715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel Phex mutation in a new mouse model of hypophosphatemic rickets.
    Owen C; Chen F; Flenniken AM; Osborne LR; Ichikawa S; Adamson SL; Rossant J; Aubin JE
    J Cell Biochem; 2012 Jul; 113(7):2432-41. PubMed ID: 22573557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition.
    Miao D; Bai X; Panda D; McKee M; Karaplis A; Goltzman D
    Endocrinology; 2001 Feb; 142(2):926-39. PubMed ID: 11159866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
    Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
    J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.
    Bresler D; Bruder J; Mohnike K; Fraser WD; Rowe PS
    J Endocrinol; 2004 Dec; 183(3):R1-9. PubMed ID: 15590969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.